National Bank of Canada FI Acquires 29,593 Shares of Humana Inc. (NYSE:HUM)

National Bank of Canada FI grew its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 54.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 83,987 shares of the insurance provider's stock after acquiring an additional 29,593 shares during the quarter. National Bank of Canada FI owned 0.07% of Humana worth $26,602,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HUM. Capital Advisors Ltd. LLC boosted its position in Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider's stock valued at $80,000 after buying an additional 31 shares during the period. CarsonAllaria Wealth Management Ltd. grew its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider's stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Moors & Cabot Inc. increased its stake in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock worth $519,000 after purchasing an additional 40 shares during the period. Harbour Investments Inc. lifted its position in Humana by 10.5% in the second quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider's stock valued at $161,000 after purchasing an additional 41 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft grew its holdings in shares of Humana by 1.0% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider's stock worth $1,649,000 after purchasing an additional 42 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

Shares of HUM traded down $0.42 on Tuesday, reaching $285.82. The company's stock had a trading volume of 1,011,218 shares, compared to its average volume of 1,844,495. The stock's 50 day simple moving average is $272.07 and its two-hundred day simple moving average is $326.37. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $34.42 billion, a P/E ratio of 25.32, a PEG ratio of 2.18 and a beta of 0.53. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $488.89.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Research analysts forecast that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana's payout ratio is presently 31.36%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HUM shares. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Humana from $349.00 to $250.00 and set a "hold" rating for the company in a report on Thursday, October 3rd. Leerink Partnrs lowered Humana from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 2nd. Jefferies Financial Group cut Humana from a "buy" rating to a "hold" rating and reduced their target price for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Oppenheimer cut their price target on shares of Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a report on Thursday, October 3rd. Finally, Wells Fargo & Company reduced their target price on Humana from $387.00 to $290.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.